Fig. 6: ASA prevents carcinogenesis of ESCC. | British Journal of Cancer

Fig. 6: ASA prevents carcinogenesis of ESCC.

From: Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells

Fig. 6

a, b Images of the oesophageal tissues of rats from DMSO, NMBzA or NMBzA+ASA group at week 25 (a) and tumour burden of each group (b). c, d Images of the oesophageal tissues of rats from DMSO, NMBzA or NMBzA+ASA group at week 35 (c) and tumour burden of each group (d). e Pathological progression from normal oesophageal epithelium to ESCC by HE staining. f, g ASA prevents lesions of all stages caused by NMBzA at week 25 (f) and week 35 (g). h IHC staining of PCNA and cyclin D1 in different pathological lesions of rat oesophagus in each group. Positive rates were calculated from six non-contiguous, randomly selected fields of each section. Scale bars, 100 μm. In all the panels, error bars indicate means ± SD; *p < 0.05, **p < 0.01; n.s., not significant. Student’s t test.

Back to article page